secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001193125-23-145197
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha completes screening for Rett syndrome gene therapy trial; reports Q1 net loss of $17.6M
--------------------------------------------------------------------------------

- Screening completed for first adult patient in Phase 1/2 REVEAL trial of TSHA-102 for Rett syndrome; dosing expected Q2 2023.
- Initial available Phase 1/2 clinical data, primarily on safety, expected in Q2 2023.
- Net loss for Q1 2023 was $17.6M ($0.28 per share) vs. $50.3M ($1.32 per share) in Q1 2022.
- Cash and equivalents $63.4M as of March 31, 2023; expected to fund operations into Q1 2024.
- FDA meeting request for TSHA-120 (GAN) regulatory path expected Q2 2023; meeting anticipated Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523145197/0001193125-23-145197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523145197/d431505d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-145197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer